Table 6.
Five-Year Total, Annual Average Totala, and Average Annual Age-Adjusted Incidence Ratesb with 95% Confidence Intervals for Selected Non-Malignant Histopathologies by Sex, Age Group at Diagnosis, Race, Hispanic Ethnicity, and Histopathology, CBTRUS Statistical Report: US Cancer Statistics – NPCR and SEER, 2015-2019
| Group | Vestibular Schwannomac | Pituitary Adenomad | WHO Grade I Meningiomae | WHO Grade II Meningiomaf | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5-Year Total | Annual Average | Rate (95% CI) | 5-Year Total | Annual Average | Rate (95% CI) | 5-Year Total | Annual Average | Rate (95% CI) | 5-Year Total | Annual Average | Rate (95% CI) | |
| Sex | ||||||||||||
| Male | 13,078 | 2,616 | 1.49 (1.47-1.52) | 29,868 | 5,974 | 3.49 (3.45-3.53) | 16,042 | 3,208 | 1.84 (1.81-1.87) | 4,050 | 810 | 0.46 (0.45-0.48) |
| Female | 14,795 | 2,959 | 1.56 (1.53-1.58) | 37,282 | 7,456 | 4.41 (4.36-4.45) | 43,389 | 8,678 | 4.47 (4.43-4.51) | 5,653 | 1,131 | 0.60 (0.58-0.61) |
| Age Groups | ||||||||||||
| 0-14 years | 213 | 43 | 0.07 (0.06-0.08) | 937 | 187 | 0.31 (0.29-0.33) | 108 | 22 | 0.04 (0.03-0.04) | 78 | 16 | 0.03 (0.02-0.03) |
| 15-39 years | 3,687 | 737 | 0.70 (0.68-0.72) | 19,150 | 3,830 | 3.56 (3.51-3.61) | 4,552 | 910 | 0.89 (0.87-0.92) | 1,063 | 213 | 0.20 (0.19-0.22) |
| 40-64 years | 14,399 | 2,880 | 2.59 (2.54-2.63) | 28,324 | 5,665 | 5.40 (5.34-5.47) | 27,964 | 5,593 | 5.03 (4.97-5.09) | 4,578 | 916 | 0.83 (0.80-0.85) |
| 65+ years | 9,574 | 1,915 | 3.74 (3.66-3.82) | 18,739 | 3,748 | 7.45 (7.34-7.56) | 26,807 | 5,361 | 10.73 (10.60-10.86) | 3,984 | 797 | 1.59 (1.54-1.64) |
| Race | ||||||||||||
| White | 23,866 | 4,773 | 1.62 (1.59-1.64) | 47,724 | 9,545 | 3.51 (3.48-3.55) | 47,661 | 9,532 | 3.15 (3.12-3.18) | 7,354 | 1,471 | 0.49 (0.48-0.51) |
| Black | 1,546 | 309 | 0.70 (0.67-0.74) | 13,520 | 2,704 | 6.24 (6.13-6.35) | 7,662 | 1,532 | 3.61 (3.53-3.69) | 1,547 | 309 | 0.71 (0.68-0.75) |
| American Indian/Alaska Native | 161 | 32 | 0.76 (0.64-0.89) | 614 | 123 | 2.90 (2.66-3.15) | 409 | 82 | 2.13 (1.92-2.35) | 57 | 11 | 0.30 (0.22-0.39) |
| Asian or Pacific Islander | 1,347 | 269 | 1.25 (1.18-1.32) | 2,883 | 577 | 2.71 (2.61-2.81) | 2,325 | 465 | 2.23 (2.13-2.32) | 507 | 101 | 0.49 (0.44-0.53) |
| Hispanic Ethnicity | ||||||||||||
| Non-Hispanic | 25,447 | 5,089 | 1.61 (1.59-1.63) | 55,782 | 11,156 | 3.82 (3.78-3.85) | 53,374 | 10,675 | 3.28 (3.25-3.31) | 8,731 | 1,746 | 0.55 (0.54-0.56) |
| Hispanic | 2,426 | 485 | 1.03 (0.99-1.07) | 11,368 | 2,274 | 4.51 (4.42-4.59) | 6,057 | 1,211 | 2.77 (2.69-2.84) | 972 | 194 | 0.43 (0.41-0.46) |
| TOTAL | 27,873 | 5,575 | 1.52 (1.50-1.54) | 67,150 | 13,430 | 3.91 (3.88-3.94) | 59,431 | 11,886 | 3.21 (3.18-3.24) | 9,703 | 1,941 | 0.53 (0.52-0.54) |
aAnnual average cases are calculated by dividing the five-year total by five.
bRates are per 100,000 and are age-adjusted to the 2000 US standard population.
cICD-O-3 histopathology code 9560/0 and ICD-O-3 topography code C72.4 and C72.5.
dICD-O-3 histopathology code 8272/0 and ICD-O-3 topography code C75.1.
eICD-O-3 histopathology codes 9530/0, 9531/0, 9532/0, 9533/0, 9534/0, and 9537/0. WHO grade may be reported according to 2007 or 2016 WHO classification depending on year of diagnosis, in which roman numerals are used to denote tumor grade.
fICD-O-3 histopathology codes 9530/1, 9531/1, 9532/1, 9533/1, 9534/1, 9537/1, 9538/1, and 9539/1. WHO grade may be reported according to 2007 or 2016 WHO classification depending on year of diagnosis, in which roman numerals are used to denote tumor grade.
- Counts and rates are not presented when fewer than 16 cases were reported for the specific category. The suppressed cases are included in the counts and rates for totals.
Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; US, United States; NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology, and End Results Program; WHO, World Health Organization; CI, confidence interval.